|
- Topoisomerase I inhibitors Based ADCs: SN-38 DXd
Although the DXd payload presented lower passive membrane permeability than exatecan mesylate, it was found to be less myelotoxic and was therefore also selected for its improved safety profile
- 8 Commonly Used ADC Payloads and Their ADME and DDI Properties - WuXi . . .
Exploring eight commonly used ADC payloads, including their toxicity, mechanisms, and highlighting their ADME DDI characteristics
- Exatecan is a Topoisomerase I Inhibitor for Cancer Therapy Research
For the past two years, DS-8201a, an ADC using Exatecan derivatives (Dxd) as effector molecules, has been on the market This has led to significant attention on drug delivery systems involving Exatecan and its derivatives
- Exatecan Mesylate in ADCs: A New Topo I Inhibitor
In this study, scientists applied the topoisomerase I inhibitor DXd to a variety of antibodies (including those that have been validated by ADC, such as anti- CD30, CD33, and CD70 antibodies), all of which demonstrated the versatility of the new payload
- Anti-DXd Exatecan payload antibody in PK study in ADC drug development
The DXD (derivative of Exatecan) is a highly effective topoisomerase I inhibitor administered in the ADCs to achieve targeted cancer therapy The part and use of anti-DXD Exatecan antibodies in PK studies play an important role in successful development and assessment of these ADCs
- DXD, a Highly Potent Tool for ADCs Pharmacokinetic Analysis . . . - Cusabio
This tool serves as a core instrument for conducting PK (Pharmacokinetic) analysis of DXD-ADCs and qualitative analysis of coupled DAR values, expediting the R D process of ADC drugs
- Payload diversification: a key step in the development of antibody–drug . . .
In a first attempt, bioconjugation of exatecan onto antibodies led to partial success with significant aggregation of the conjugate This issue was solved by Daiichi Sankyo scientists by using a slightly modified glycolic acid derivative of exatecan, named DXd
- Exatecan – Knowledge and References – Taylor Francis
Exatecan is a drug that is a structural analog of camptothecin and has antineoplastic activity It has been found to have a useful anticancer effect on advanced peritoneal, ovarian, and tubal cancer when other anticancer agents have failed
|
|
|